• Sulfo-Cy5 NHS Ester: Aqueous Protein Labeling

  2026-09-17

  Sulfo-Cy5 NHS ester is a sulfonated, amine-reactive fluorescent reagent for aqueous protein conjugation. Its reported 646 nm excitation maximum, 662 nm emission maximum, and high extinction coefficient support sensitive fluorescence imaging when labeling, cleanup, storage, and target controls are properly managed.

• Fenofibrate: Reliable Assay Design for Cell Studies

  2026-09-17

  This scenario-driven guide explains how Fenofibrate (SKU B1943) can support interpretable cell viability, proliferation, cytotoxicity, and PPARα–YAP experiments. It covers formulation, concentration planning, time-course design, data interpretation, and practical supplier-selection criteria.

• LIRP Enables Light-Controlled Gene Therapy

  2026-09-16

  A 2026 Trends in Biotechnology study describes a rationally designed light-inducible RNA-releasing protein (LIRP) that controls therapeutic protein production at the translation stage. In mouse models, LIRP-regulated AAV systems enabled ambient-light activation for metabolic disease and reversible light-dependent interruption of retinal VEGF inhibition.

• Low-Cost Microfluidic Mixers for LNP Research

  2026-09-16

  The 2025 Pharmaceutics study evaluates two low-cost microfluidic mixers against pipette mixing for lipid nanoparticle manufacture. Its central finding is that inexpensive approaches can produce well-encapsulated LNPs and support useful high-throughput screening, although orthogonal characterization remains necessary because similar size and encapsulation values can conceal functional differences.

• HMGB1 Proteomics for Early Diabetic Nephropathy

  2026-09-15

  The iScience study integrates quantitative serum proteomics with Mfuzz clustering and WGCNA to identify proteins that track diabetic nephropathy progression, highlighting HMGB1 as a candidate early-monitoring biomarker. Its findings support a staged, multi-method strategy in which discovery proteomics is followed by orthogonal validation rather than immediate clinical adoption.

• Fasting, eIF4E Phosphorylation, and Tumor Metabolism

  2026-09-15

  The reference study identifies phosphorylation of eIF4E as a selective translational control mechanism that enables the liver to produce ketone bodies during fasting and ketogenic feeding, even while overall protein synthesis declines. Its findings connect fatty-acid sensing through the AMPK–MNK–eIF4E axis with pancreatic tumor adaptation and suggest a diet–drug strategy for testing tumors that depend on ketone metabolism.

• αKG–Carnitine Control of DNA Repair and PARP Response

  2026-09-14

  The reference study identifies an αKG–TMLHE–carnitine pathway that sustains histone acetylation and homologous recombination in otherwise HR-proficient cancer cells. Its findings connect metabolic state to resistance against Olaparib, cisplatin, and radiation, suggesting a route for inducing functional HR deficiency without relying exclusively on BRCA1 or BRCA2 mutations.

• Novobiocin in Reliable Cell Assays

  2026-09-14

  Learn how Novobiocin (SKU BA1116) can be incorporated into reproducible cell viability, proliferation, cytotoxicity, antiparasitic, and antiviral workflows. This scenario-based guide covers solvent controls, concentration selection, interpretation, and practical product-selection criteria.

• Vancomycin hydrochloride: Applied Research Workflows

  2026-09-13

  Vancomycin hydrochloride is more than a Gram-positive control: it can anchor antibiotic resistance assays, bacterial susceptibility testing, and selective recovery workflows. The reference study shows how vancomycin-based selection can improve Moraxella isolation from contaminated bovine specimens when paired with confirmation testing.

• 3-Deazaadenosine: An Assay-Design Guide

  2026-09-12

  3-Deazaadenosine is an S-adenosylhomocysteine hydrolase inhibitor for dissecting methylation-dependent biology. This guide connects its biochemical action with the METTL14–DHRS4-AS1 axis in ulcerative colitis and develops a practical framework for interpreting chemical perturbation in antiviral and inflammatory assays.

• ONX-0914 (PR-957) Immunoproteasome Research

  2026-09-11

  ONX-0914, also known as PR-957, is a selective LMP7 immunoproteasome inhibitor used to study cytokine regulation and immune-mediated disease models. Supplier-reported and peer-reviewed evidence supports applications in autoimmune, arthritis, diabetes, colitis, and airway inflammation research, while also showing that biological effects depend on tissue context.

• Necrostatin-1: RIP1 Kinase Inhibitor Workflows

  2026-09-11

  Necrostatin-1 provides a practical way to test whether inflammatory or tissue-injury phenotypes depend on RIP1-driven necroptosis. This guide connects cell-based necroptosis assays, AKI models, and ferroptosis-focused cancer research while emphasizing controls, formulation, and interpretation limits.

• D-Luciferin for Glioma Bioluminescence Imaging

  2026-09-10

  D-Luciferin potassium salt converts luciferase-labeled tumor burden into a longitudinal, non-invasive readout for glioma, cell-tracking, and reporter studies. This workflow-focused guide explains substrate preparation, IVIS timing, assay controls, and troubleshooting for more reproducible in vivo bioluminescence imaging.

• QNZ (EVP4593) for NF-κB Assay Design

  2026-09-10

  QNZ (EVP4593) provides a nanomolar pharmacological perturbation tool for connecting NF-κB activity with inflammatory cytokines, viability, and calcium signaling. Its value extends from Jurkat reporter assays to Huntington’s disease research, while the reference study suggests a practical framework for testing tissue-specific natural-product mechanisms.

• Etoposide (VP-16): From DNA Breaks to Translation

  2026-09-09

  Etoposide (VP-16) is more than a conventional DNA-damaging reagent: it is a translational benchmark for connecting topoisomerase II engagement, DNA double-strand break signaling, apoptosis, and cell-state selectivity. This article presents a practical framework for using Etoposide in DNA damage assays, cancer chemotherapy research, and exploratory senescence biology while distinguishing validated evidence from forward-looking hypotheses.

8129 records 4/542 page Previous Next 12345 下5页 Last page